Company news
Bristol-myers Squibb Company (NYSE:BMY) news
Every Bristol-myers Squibb Company press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic ...
August 29, 2026
FESTIVAL ANNOUNCEMENT: 32nd Annual One Mind Music Festival Presented by Bank of America and Bristol Myers Squibb
August 19, 2026
Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for ...
August 19, 2026
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyalur...
August 13, 2026
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
August 10, 2026
Bristol Myers Squibb Reports Second Quarter Financial Results for 2026
July 30, 2026
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA
July 20, 2026
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refrac...
July 13, 2026
BREYANZI® CAR T Cell Therapy Monitoring and Activity Updates Approved in Canada
June 17, 2026
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavac...
June 1, 2026
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced...
June 1, 2026
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Sma...
May 30, 2026
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in R...
May 29, 2026
Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfol...
May 21, 2026
Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Acros...
May 20, 2026
Tigerlily Foundation Collaborates with Bristol Myers Squibb to Advance Clinical Trial Access and Equity
May 15, 2026
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Progra...
May 14, 2026
Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Im...
May 12, 2026
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis i...
May 8, 2026
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
May 7, 2026
Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026
May 6, 2026
Bristol Myers Squibb Launches "Won't Lose" Media Campaign Ahead of FIFA World Cup 2026™
May 4, 2026
Bristol Myers Squibb Reports First Quarter Financial Results for 2026
April 30, 2026
Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
April 24, 2026
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
April 23, 2026
Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic...
April 21, 2026
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
April 20, 2026
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs
April 16, 2026
Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers f...
April 9, 2026
Bristol Myers Squibb : Preliminary Q1 2026 Acquired IPRD & Licensing Income
April 3, 2026
Bristol Myers Squibb Evolves and Expands Standing in the Gaap To Advance More Equitable Care in Multiple Myeloma As Program Marks Ten Years
April 1, 2026
Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years
March 31, 2026
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in ...
March 29, 2026
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanome...
March 28, 2026
A New Era in Schizophrenia Care: National Council for Mental Wellbeing and Bristol Myers Squibb Collaborate to Advance Evidence-Based Car...
March 27, 2026
insitro and Bristol Myers Squibb Collaboration Expanded with Nomination of New Targets
March 23, 2026
Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific...
March 23, 2026
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivol...
March 20, 2026
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
March 19, 2026
Colgate-Palmolive Announces Quarterly Dividend Increase and Elects Christopher Boerner, Ph.D. to Board of Directors
March 12, 2026
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple...
March 9, 2026
U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
March 6, 2026
Bristol Myers Squibb Announces Dividend
March 2, 2026
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previo...
February 26, 2026
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
February 23, 2026
Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thala...
February 23, 2026
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
February 19, 2026
Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accele...
February 18, 2026
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refract...
February 17, 2026